The Journal of Clinical Endocrinology & Metabolism · 2001 · 92 citations · 43 references
Life SciencesBiochemistryEndocrinologyProtein BiochemistryProtein-protein InteractionsProteomicsPlasma ProteinsProtein DegradationProteolytic EnzymesProteolytic ProcessingExtracellular ProteasesPrimary ProteolysisProtease Cleavage SpecificityProtease-mediated Protein DegradationProteolytic ActivityProteolytic Enzyme ActivityProteolytic PathwaysProteolytic Stability
Pregnancy-associated plasma protein-A (PAPP-A) has been identified as the insulin-like growth factor (IGF)-dependent IGF-binding protein-4 (IGFBP-4) protease produced by human fibroblasts. Recently, we found that serum proteases induced during human pregnancy cleaved IGFBP-4 in both an IGF-II-dependent and an IGF-II-independent fashion. This study sought to determine whether PAPP-A is the predominant IGFBP-4 protease in human pregnancy serum (PS) and to assess the in vitro role of serum PAPP-A. Immunoprecipitation with PAPP-A antibody effectively depleted PAPP-A from the PS and completely abolished both IGF-II-dependent and IGF-II-independent IGFBP-4 proteolytic activity in PS. Direct addition of PAPP-A antibody to PS completely blocked IGFBP-4 proteolysis and partially blocked IGFBP-5 proteolysis, but had no effect on IGFBP-3 proteolysis. To evaluate the role of serum PAPP-A, we tested whether PAPP-A in PS modulated the inhibitory activity of IGFBP-4 on IGF-II-induced cell proliferation in human osteosarcoma MG63 cells. The wild-type IGFBP-4 (WTBP-4; 200 ng/mL) failed to inhibit proliferation of the cells treated with PS (0.1% or 0.3%) alone or in combination with IGF-II (40 ng/mL), whereas the inhibitory effect of WTBP-4 was observed in the cells treated with nonpregnancy serum alone or in combination with IGF-II (P < 0.05). In contrast to WTBP-4, a protease-resistant IGFBP-4 was able to inhibit proliferation of the cells treated with PS alone or in combination with IGF-II (P < 0.05). In the presence of PAPP-A neutralizing antibody, the inhibitory effect of WTBP-4 on proliferation of the cells treated with IGF-II and PS was restored. In summary, these data demonstrate 1) that PAPP-A represents the predominant IGFBP-4 protease in PS; 2) that PAPP-A may in part contribute to IGFBP-5, but not IGFBP-3, proteolytic activity in PS; and 3) that PAPP-A enhances the bioactivity of IGFs in vitro by degrading IGFBP-4.
43
Role of insulin-like growth factors in embryonic and postnatal growth
Julie C. Baker, Jeh-Ping Liu, Elizabeth J. Robertson et al. · Cell · 1993 · 2.4K citations
James Lawrence, Claus Oxvig, Michael T. Overgaard et al. · Proceedings of the National Academy of Sciences · 1999 · 707 citations
Linda C. Giudice, ELEANOR M. FARRELL, Hung Pham et al. · The Journal of Clinical Endocrinology & Metabolism · 1990 · 366 citations
Linda C. Giudice, Francis de Zegher, Sharron Gargosky et al. · The Journal of Clinical Endocrinology & Metabolism · 1995 · 365 citations